BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cangen Biotechnologies, Inc. And Olympus To Collaborate On Development Of High-Throughput Molecular Diagnostic Test For Lung Cancer


10/19/2005 5:09:48 PM

BETHESDA, Md.--(BUSINESS WIRE)--May 25, 2005--Cangen Biotechnologies, Inc. today announced a research collaboration with Olympus Corporation for the development of a hybrid DNA-based and protein-based diagnostic test for use in the detection of lung cancer. This collaboration will provide Cangen Biotechnologies with access to Olympus' microarray technology to enable the DNA-based portion of the test allowing high-throughput testing for lung cancer. Under the terms of the agreement, Olympus is responsible for refining and further developing its microarray technology in an effort to accommodate Cangen's development of the hybrid DNA-based and protein-based diagnostic test for the detection of lung cancer. "We are excited about this opportunity to work in collaboration with Olympus in an effort to develop an accurate and cost-effective test to detect lung cancer in early stages," stated Chul So Moon, M.D., Ph.D., Chief Executive Officer and Chief Science Officer of Cangen Biotechnologies. "Such a test would enable the improvement of medical care for people all around the world," Dr. Moon added.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES